NCT04139330终止2 期
A Multicenter, Double-blind, Randomized, Placebo-controlled Parallel Group Trial to Investigate the Proof of Concept of NPC-06 to Acute Pain in Herpes Zoster
Nobelpharma1 个研究点 分布在 1 个国家目标入组 16 人开始时间: 2019年11月21日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- 入组人数
- 16
- 试验地点
- 1
- 主要终点
- The improvement of NRS (Numeric Rating Scale:Max10, Min0, higher scores mean a worse outcome) score
研究概览
简要总结
The purpose of this trial is to investigate the efficiency of pain relief and the safety of NPC-06 for the acute pain in herpes zoster in the placebo-controlled double-blind parallel group trial, in addition to explore the effective concentration of NPC-06.
详细描述
The eligible patients will be randomized into three groups, and will receive single doses of NPC-06 (high dose and low dose) or placebo.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •20 years old or over at the time of informed consent.
- •Both genders.
- •Patients who have acute rash (either erythema or papule or bulla or pustule, or more), except who have crust more than 20% of entire rash at just before the time of the first administration.
- •Patients who are administrated antiviral drug for herpes zoster at the time of the first administration.
- •Patients who are administrated non-opioid analgesics(acetaminophen, NSAIDs) for herpes zoster at the time of the first administration.
- •Patients who the NRS score at the time of below evaluation point is higher than
- •120 minutes before the start of infusion.
- •Just before the start of infusion.
- •Patients who the therapeutic effect of non-opioid analgesics for herpes zoster has been insufficient.
- •Patients who can admit to hospital for the all assessment duration from first administration until next day (including hospitalized patient).
- •Patients or his/her guardian who give a written informed consent in understanding and willingness after having received enough explanation regarding the study participation.
排除标准
- •Patients who cannot evaluate NRS by themselves.
- •Patients who are suspected to intracranial pressure increase.
- •Patients who have epilepsy, serious psychiatric or serious neurological disease (i. e. dementia, Parkinson disease and schizophrenic disorder) or consciousness disorder.
- •Patients who have malignant tumors (except for patients who have no signs of recurrence under treatment) or patients who are under treatment for HIV or patients who are receiving immunosuppressant.
- •Patients who have complicated idiopathic trigeminal neuralgia.
- •Patients who have other serious pain which may affect the evaluation of acute herpetic pain.
- •Patients who are receiving opioids or steroids(systemic).
- •Patients who have sinus bradycardia or serious disturbance of conduction system.
- •Patients who have history of hypersensitivity against hydantoin compound.
- •Patients who are receiving tadalafil (for pulmonary hypertension), rilpivirine, asunaprevir, daclatasvir, vaniprevir, macitentan or sofosbuvir.
- •Patients who are receiving medications for neuropathic pain, antidepressants, antiarrhythmic drugs, N-methyl-D-aspartate receptor antagonists, muscle relaxants, local anesthetics, an extract from inflammatory rabbit skin inoculated by vaccinia virus, Chinese herbal medications for analgesia, vitamin B
- •Patients who are receiving amenamevir.
- •Patients who have meningitis or meningeal irritation signs.
- •Patients who have complications such as serious heart disease, hepatic function disorder or renal function disorder which severity are considered by investigator as grade 3 or more severe with reference to ''Concerning classification criteria for seriousness of adverse drug reactions of medical agents'' .
- •Patients who are receiving fosphenytoin, phenytoin or ethotoin and combination drug including these or have taken these drugs as adjuvant therapy for pain .
研究组 & 干预措施
NPC-06 (high dose)
Experimental
Infuse diluted NPC-06 18mg/kg solution with 3 to 4 times volume of saline. Administarate NPC-06 gradually (slowly) over 18 minutes.
干预措施: NPC-06 (Drug)
NPC-06 (low dose)
Experimental
Infuse diluted NPC-06 12mg/kg solution with 3 to 4 times volume of saline. Administarate NPC-06 gradually (slowly) over 12 minutes
干预措施: NPC-06 (Drug)
NPC-06 (placebo)
Placebo Comparator
Infuse NPC-06 (placebo) over 12 minutes or 18 minutes
干预措施: NPC-06 (Drug)
结局指标
主要结局
The improvement of NRS (Numeric Rating Scale:Max10, Min0, higher scores mean a worse outcome) score
时间窗: 120 minutes after first administration
The average change (slope) of NRS score at the time of evaluation, which is measured before the first administration, 30, 60, 90 and 120 minutes after the first administration.
次要结局
- The improvement of NRS (Numeric Rating Scale:Max10, Min0, higher scores mean a worse outcome) score(120 minutes after first administration)
- The improvement of QOL(EQ-5D-5L, Max 1.000, Min -0.111, higher scores mean a better outcome) score(7 days)
研究者
研究点 (1)
Loading locations...
相似试验
终止
2 期
Phase II Clinical Trial of NPC-06 in Patients With Neuropathic Pain in CancerNeuropathic Pain in CancerNCT03773055Nobelpharma7
Unknown
1 期
Diabetic Neuropathic Pain Relief, 6 Weeks Dosage Sublingual Water-soluble CBD/PEADiabetic Peripheral Neuropathic PainNCT05766969Pure Green Pharmaceuticals Inc.52
已完成
3 期
A Study of Extended-Release Hydrocodone/Acetaminophen (Vicodin CR®) in Subjects With Acute Pain Following BunionectomyPainNCT00402792Abbott150
已完成
2 期
A Study Comparing the Analgesic Efficacy and Safety of Extended Release Hydrocodone/Acetaminophen (Vicodin® CR)and Placebo in Subjects With OsteoarthritisPainNCT00404183Abbott120
已完成
2 期
A Study Comparing Vicodin® CR and NORCO® to Placebo in Subjects With Acute Pain Following BunionectomyPainNCT00404222Abbott90